INSIGHT 2 : a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance
Bron
Future oncology - ISSN 1479-6694- () p.
Tepotinib treatment in patients with MET exon 14-skipping non-small cell lung cancer long-term follow-up of the VISION phase 2 nonrandomized clinical trial
Bron
JAMA oncology - ISSN 2374-2437-9:9 (2023) p. 1260-1266
Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma
Bron
Frontiers in immunology - ISSN 1664-3224-14 (2023) p. 1-11
Plain language summary of the development of tepotinib : a treatment for a subtype of non-small cell lung cancer called 'MET exon 14 skipping'
Bron
Future oncology - ISSN 1479-6694-19:10 (2023) p. 679-736
Surgical series in mesothelioma : navigating between biases
Bron
Translational lung cancer research - ISSN 2218-6751-12:2 (2023) p. 184-186